What is the latest news about Acotiamide in 2025?

Acotiamide has once again attracted attention in the field of functional dyspepsia (Functional Dyspepsia, FD). This acetylcholinesterase inhibitor developed by Japan's Zeria Pharmaceuticals, with the trade name Acofide (Japan) or Dyspevict (Russia), has been included in the treatment guidelines of many countries since it was officially launched in Japan in 2013. It is used to relieve symptoms such as postprandial fullness, upper abdominal discomfort and early satiety. The research focus in 2025 will mainly focus on the extension of its pharmacological mechanism, expansion of indications and regulatory developments in markets outside Asia.

International pharmacological research shows that the mechanism of action of acotiamide is not only limited to inhibiting acetylcholinesterase activity, thereby enhancing the nerve signaling of acetylcholine, but also involves the improvement of gastric emptying regulation and adaptive gastric relaxation. A study jointly released by Tokyo Medical University in Japan and the European Society of Gastrointestinal Dynamics at the end of 2024 pointed out that acotiamide can improve gastric motility disorders by regulating vagus nerve activity, and can significantly alleviate postprandial symptoms in patients with non-ulcer functional dyspepsia.

In terms of international market expansion, the Russian versionDyspevict expanded its clinical use scope through an updated drug registration process in early 2024, and some Eastern European countries have included it in the recommended list for first-line treatment of functional dyspepsia. At the same time, the introduction and cooperation in the Middle East and Southeast Asian markets are also progressing. The results of multi-center trials in India and Singapore show that the efficacy of acotiamide in patients with delayed gastric emptying is longer-lasting and safer than traditional prokinetic drugs such as domperidone.

In addition,The latest pharmacoeconomics study in 2025 proposed that long-term use of acotiamide not only improves gastric symptoms, but also improves patients’ quality of life index (QoL), showing a good cost-effectiveness ratio in the management of chronic digestive system diseases. This makes acotiamide expected to become one of the core drugs for the treatment of functional dyspepsia in the future.

Reference: https://www.rad-ar.or.jp/siori/english/search/result?n=33322